US6221352B1
(en)
|
1989-03-21 |
2001-04-24 |
The Immune Response Corporation |
Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
|
US5612035A
(en)
*
|
1989-03-21 |
1997-03-18 |
The Immune Response Corporation |
Vaccination against diseases resulting from pathogenic responses by specific T cell populations
|
US6207645B1
(en)
*
|
1989-03-21 |
2001-03-27 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
|
US5776459A
(en)
*
|
1989-07-19 |
1998-07-07 |
Connetics Corporation |
TCR V beta 5 peptides
|
US5298396A
(en)
*
|
1989-11-15 |
1994-03-29 |
National Jewish Center For Immunology And Respiratory Medicine |
Method for identifying T cells disease involved in autoimmune disease
|
JPH06507384A
(ja)
*
|
1991-01-22 |
1994-08-25 |
ザ イミューン レスポンス コーポレイション |
特定のt細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
|
JPH07502977A
(ja)
*
|
1991-05-31 |
1995-03-30 |
ゾーマ・コーポレーション |
免疫関連疾患用治療薬としてのt細胞レセプターペプチド
|
EP0602178A4
(en)
*
|
1991-08-28 |
1995-10-25 |
Wistar Inst |
T cell receptor-based therapy for rheumatoid arthritis.
|
JPH06511241A
(ja)
*
|
1991-09-23 |
1994-12-15 |
ジェネンテク,インコーポレイテッド |
自己免疫疾患の診断および治療
|
EP0623025A1
(en)
*
|
1991-12-24 |
1994-11-09 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
|
AU4529793A
(en)
*
|
1992-06-08 |
1994-01-04 |
Colorado State University Research Foundation |
Endogenous ligands for cdr4 of t-cell receptor beta -chains and genes encoding the same
|
EP0698087A1
(en)
*
|
1993-05-14 |
1996-02-28 |
Dr. L. Willems Instituut |
Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
|
US5552300A
(en)
*
|
1994-01-13 |
1996-09-03 |
T Cell Sciences, Inc. |
T cell antigen receptor V region proteins and methods of preparation thereof
|
US6034064A
(en)
*
|
1995-04-07 |
2000-03-07 |
Hoechst Pharmaceuticals & Chemicals K.K. |
Peptides and therapeutic agent for autoimmune diseases containing the same
|
AU2001268363B2
(en)
|
2000-06-20 |
2006-08-17 |
Biogen Idec Inc. |
Treatment of B cell associated diseases
|
JP2005503999A
(ja)
|
2001-01-31 |
2005-02-10 |
アイデック ファーマスーティカルズ コーポレイション |
腫瘍性疾患の治療のためのcd23拮抗剤の使用
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
ES2322267T3
(es)
|
2003-04-09 |
2009-06-18 |
Genentech, Inc. |
Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
|
MXPA06014069A
(es)
|
2004-06-04 |
2007-04-25 |
Genentech Inc |
Metodo para tratar esclerosis multiple.
|
KR101289537B1
(ko)
|
2005-02-15 |
2013-07-31 |
듀크 유니버시티 |
항-cd19 항체 및 종양학에서 이의 용도
|
EP1869076A2
(en)
|
2005-03-10 |
2007-12-26 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
AU2006244445B2
(en)
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
WO2008137915A2
(en)
|
2007-05-07 |
2008-11-13 |
Medimmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
ES2824261T3
(es)
|
2007-09-14 |
2021-05-11 |
Biogen Ma Inc |
Composiciones y procedimientos para el tratamiento de la leucoencefalopatía multifocal progresiva (LMP)
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
EP2113560A1
(en)
*
|
2008-04-28 |
2009-11-04 |
TXCell |
Compositions for treating an arthritic condition
|
CA2723614C
(en)
|
2008-05-16 |
2015-07-14 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
CN102317314A
(zh)
|
2008-10-10 |
2012-01-11 |
阿纳福公司 |
结合trail-r1和trail-r2的多肽
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
ES2513292T3
(es)
|
2009-07-31 |
2014-10-24 |
Genentech, Inc. |
Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
BR112012005670A2
(pt)
|
2009-09-17 |
2017-01-10 |
Hoffmann La Roche |
''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
RU2580038C2
(ru)
|
2009-12-04 |
2016-04-10 |
Дженентек, Инк. |
Мультиспецифические антитела, аналоги антител, композиции и способы
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011133886A2
(en)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
TWI603738B
(zh)
|
2010-11-08 |
2017-11-01 |
建南德克公司 |
皮下投予抗-il-6受體抗體
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CN103649117B
(zh)
|
2011-02-04 |
2016-09-14 |
霍夫曼-拉罗奇有限公司 |
Fc变体及其生成方法
|
EP2691113A4
(en)
|
2011-03-31 |
2014-12-24 |
Hoffmann La Roche |
METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
CA2842481A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
AU2013215332A1
(en)
|
2012-01-31 |
2014-09-04 |
Genentech, Inc. |
Anti-Ig-E M1' antibodies and methods using same
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
RU2659423C2
(ru)
|
2012-02-16 |
2018-07-02 |
ЭйТИР ФАРМА, ИНК. |
ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
|
MX2014014804A
(es)
|
2012-06-27 |
2015-02-12 |
Hoffmann La Roche |
Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
|
CA2871880A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
JP6449161B2
(ja)
|
2012-10-05 |
2019-01-09 |
ジェネンテック, インコーポレイテッド |
炎症性腸疾患の診断治療方法
|
CN105247072B
(zh)
|
2013-02-25 |
2019-10-15 |
基因泰克公司 |
检测和治疗抗药性akt突变体的方法和组合物
|
US9682071B2
(en)
|
2013-03-15 |
2017-06-20 |
Intermune, Inc. |
Methods of improving microvascular integrity
|
AU2014241552B2
(en)
|
2013-03-27 |
2018-08-16 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
MX2016012282A
(es)
|
2014-03-27 |
2017-01-06 |
Genentech Inc |
Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
|
KR102603417B1
(ko)
|
2014-05-06 |
2023-11-20 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
LT3227336T
(lt)
|
2014-12-05 |
2019-09-25 |
F. Hoffmann-La Roche Ag |
Anti-cd79b antikūnai ir jų naudojimo būdai
|
CA2972099A1
(en)
|
2015-02-26 |
2016-09-01 |
Genentech, Inc. |
Integrin beta7 antagonists and methods of treating crohn's disease
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
BR112017024610A2
(pt)
|
2015-06-24 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
anticorpos para receptor antitransferrina com afinidade especificada
|
KR20180021864A
(ko)
|
2015-06-29 |
2018-03-05 |
제넨테크, 인크. |
장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
MA43023A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
WO2017062682A2
(en)
|
2015-10-06 |
2017-04-13 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
BR112018010945A2
(pt)
|
2015-12-30 |
2018-12-04 |
Genentech Inc |
formulações com degradação de polissorbato reduzida
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
CA3045296A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
CA3045472A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
US10980739B2
(en)
|
2016-12-14 |
2021-04-20 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
TW201834690A
(zh)
|
2016-12-14 |
2018-10-01 |
美商寶珍那提公司 |
以免疫抑制劑治療胃腸道疾病
|
MX2019006864A
(es)
|
2016-12-14 |
2019-10-15 |
Progenity Inc |
Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).
|
US11426566B2
(en)
|
2016-12-14 |
2022-08-30 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a TLR modulator
|
EP3554540B1
(en)
|
2016-12-14 |
2023-08-02 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
|
KR20190097107A
(ko)
|
2016-12-14 |
2019-08-20 |
프로제너티, 인크. |
Jak 저해제로의 위장관 질환의 치료 및 장치
|
WO2018183941A2
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
US20200094031A1
(en)
|
2017-03-30 |
2020-03-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
WO2018183931A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
EP3672586A1
(en)
|
2017-08-23 |
2020-07-01 |
Kezar Life Sciences |
Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
EP3802850A1
(en)
|
2018-06-01 |
2021-04-14 |
Progenity, Inc. |
Devices and systems for gastrointestinal microbiome detection and manipulation
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
WO2020086858A1
(en)
|
2018-10-24 |
2020-04-30 |
Genentech, Inc. |
Conjugated chemical inducers of degradation and methods of use
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
US20220249814A1
(en)
|
2018-11-19 |
2022-08-11 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
WO2020104705A2
(en)
|
2018-11-23 |
2020-05-28 |
Katholieke Universiteit Leuven |
Predicting a treatment response in inflammatory bowel disease
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
CN112805026A
(zh)
|
2019-02-06 |
2021-05-14 |
桑格摩生物治疗股份有限公司 |
用于治疗i型黏多糖贮积症的方法
|
US20200316116A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Method for the treatment of beta-thalassemia
|
CN115666704A
(zh)
|
2019-12-13 |
2023-01-31 |
比奥拉治疗股份有限公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2023086910A1
(en)
|
2021-11-12 |
2023-05-19 |
Genentech, Inc. |
Methods of treating crohn's disease using integrin beta7 antagonists
|
WO2024127332A1
(en)
|
2022-12-14 |
2024-06-20 |
Pheon Therapeutics Ltd |
Cytotoxic compounds
|